Cancer Biomarkers Market Set to Reach US$ 20.48 billion by 2022 Growing at 12.2% CAGR - Overview by Top Executives of QIAGEN, Roche, Abbott and Thermo Fisher in North America and Europe

#Major players in cancer biomarkers market that are profiled in the report includes Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson (US), Hologic (US), Danaher (US), and Shimadzu (Japan).
Access Sample Papers of Cancer Biomarkers Market Report Now at http://www.reportsnreports.com/contacts/requestsample.aspx?name=420487 .

Cancer biomarkers market has evolved significantly owing to rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, & rising demand for personalized medicine in cancer therapies. However, an unfavorable regulatory & reimbursement scenario & high capital investments required for biomarker development & validation are some factors expected to restrain market.

Major factors driving growth of cancer biomakers market are rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, and rising demand for personalized medicine in cancer therapies.

Key Target Audience:
• Manufacturing companies of diagnostics kits and imaging instrument providers
• Biomarkers assay and reagent manufacturers, vendors, and distributors
• Contract research organizations (CROs)
• Companies offering platforms/technologies for cancer diagnosis
• Market research and consulting firms
• Venture capitalists and investors

Complete report on Cancer Biomarkers Market spread across 267 Pages, 16 Companies and Supported with 268 Tables and 37 Figures is now available at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=420487 .

The global cancer biomarkers market is accounted for USD 10.31 Billion in 2016 and is expected to grow at a CAGR of 12.2% to USD 20.48 Billion by 2022 during the forecast period. They enhance cancer detection and facilitate high-speed noninvasive diagnosis using genomics and proteomics. High cost of various cancer diagnostic tests, need for high capital investments, poorly suited regulatory and reimbursement systems, and technical issues related to sample collection are restricting the growth of this market.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–40%, Tier 2–30%, and Tier 3–30%
• By Designation–Director level–18%, C-Level–27%, and Others–55%
• By Region – North America–50%, Europe–20%, Asia-Pacific–20%, and RoW–10%

More Detailed Information on “Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022” research report can be requested at http://www.reportsnreports.com/contacts/discount.aspx?name=420487 .

The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin’s lymphoma, kidney, and other cancers. The lung cancer segment is expected to register the highest CAGR during the forecast period. The increasing company focus on research on lung cancer biomarkers is the key driver for this market.

It focuses on emerging and high-growth segments, and high-growth regions. The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on key players in the cancer biomarkers market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future.

ReportsnReports is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

Snehal Shete
Tower B5, Office 101,
Magarpatta City SEZ,
Pune-411013, India
sales@reportsandreports.com / Call +1 888 391 5441

This release was published on openPR.